Scholarlink

Background <p>Oral levodopa is currently the most effective treatment for Parkinson’s disease (PD). However, many patients will suffer fluctuations as the disease progresses. CVT-301, an inhaled levodopa powder, has shown promise in clinical trials for managing OFF periods without severe side effects, yet real-world data are lacking.</p> Objectives <p>To assess clinical effectiveness and tolerance of inhaled levodopa in PD patients.</p> Methods <p>observational study based on a retrospective chart review of consecutive PD patients treated with inhaled levodopa from April 2023 to May 2024.</p> Results <p>twenty-eight patients were included. Twenty (71.4%) reported improvement of OFF symptoms, with benefits appearing within 10&#xa0;min in most patients. Adverse events were common. Only 2 (7.1%) discontinued treatment due to severe coughing.</p> Conclusions <p>Inhaled levodopa offers rapid improvement in PD symptoms with acceptable tolerance. This real-world study underscores its potential benefit for PD-related fluctuations, widening on demand options for patients inadequately controlled by oral medications.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Inhaled levodopa in Parkinson´s disease with motor fluctuations: post-commercialization experience in two movement disorders units

  • 期刊论文

  • 发表日期：

    2026年4月21日

查看全文
  • Pablo Ros-Arlanzón,
  • Noelia Valverde-Mata,
  • Maria-Luisa Almarcha-Menargues,
  • Ángeles Patiño,
  • Araceli Alonso-Cánovas,
  • Paula Pérez-Torre,
  • José Luis López-Sendón,
  • Samira Fanjul,
  • Mónica M. Kurtis,
  • Juan Carlos Martínez-Castrillo,
  • Isabel Pareés

摘要

Background

Oral levodopa is currently the most effective treatment for Parkinson’s disease (PD). However, many patients will suffer fluctuations as the disease progresses. CVT-301, an inhaled levodopa powder, has shown promise in clinical trials for managing OFF periods without severe side effects, yet real-world data are lacking.

Objectives

To assess clinical effectiveness and tolerance of inhaled levodopa in PD patients.

Methods

observational study based on a retrospective chart review of consecutive PD patients treated with inhaled levodopa from April 2023 to May 2024.

Results

twenty-eight patients were included. Twenty (71.4%) reported improvement of OFF symptoms, with benefits appearing within 10 min in most patients. Adverse events were common. Only 2 (7.1%) discontinued treatment due to severe coughing.

Conclusions

Inhaled levodopa offers rapid improvement in PD symptoms with acceptable tolerance. This real-world study underscores its potential benefit for PD-related fluctuations, widening on demand options for patients inadequately controlled by oral medications.